TABLE 1.
Patients' characteristics
| Patient characteristic | Drug‐naïve group (N = 47) | Drug‐managed group (N = 115) | p‐Value |
|---|---|---|---|
| Gender (male:female) | 22:25 | 65:50 | .061 |
| Age (years, mean ± SD) | 57.72 ± 10.085 | 60.44 ± 9.581 | .109 |
| Duration of disease (years, median (range)) | 1.82 (0.08–10.25) | 3.47 (0.08–26.37) | .005* |
| UPDRS III score (median (range)) | 18 (4–68) | 19 (3–66) | .002* |
| H–Y stage (median (range)) | 2 (1–3) | 2.5 (1–5) | <.001* |
| LEED (median (range)) | — | 425 (25–1,300) | NA |
| Duration of treatment (years, median (range)) | — | 2.04 (0.04–26.37) | NA |
| MMSE (median (range)) | 28 (19–30) | 28 (17–30) | .497 |
| Education (median (range)) | 9 (0–18) | 9 (0–18) | .459 |
Note: p < .05 was considered statistically significant (annotated with *).
Abbreviations: H–Y stage, Hoehn and Yahr stage; LEDD, levodopa equivalent daily dose; MMSE, Mini‐Mental State Examination; NA, not available; UPDRS III, the Unified Parkinson's Disease Rating Scale Part III.